ArticleDrug safety2023
Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping Review.
Article in Drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine Learning in HIV Care and Antiretroviral Therapy: Systematic Review.Journal of medical Internet research · 2026Pooled it
- Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics.Clinical pharmacology and therapeutics · 2026Article
- Comparison of a pharmacovigilance screening heuristic with expert clinical consensus for adverse drug reaction signal classification at a Pakistani tertiary care hospital.Pakistan journal of medical sciences · 2026Article
- Characterization and comparison of structured and unstructured electronic health record data mapped to MedDRA for post-marketing surveillance.JAMIA open · 2026Article
- Adverse drug-event detection using the tree-based scan statistics (TreeScan) and comparison with common mining methods: new user, propensity score-matched cohorts.European journal of clinical pharmacology · 2026Article
- Recommendations to Enable Broader Use of Real-World Evidence to Inform Decision-Making Throughout Pharmacovigilance Signal Management.Pharmacoepidemiology and drug safety · 2025Review
- Pretrained patient trajectories for adverse drug event prediction using common data model-based electronic health records.Communications medicine · 2025Article
- Mitigation of outcome conflation in predicting patient outcomes using electronic health records.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Label-Free Electrochemical Cell-Based Biosensor for Toxicity Assay of Water-Soluble Form of Phosphatidylcholine.Biomedicines · 2025Article
- Leveraging Natural Language Processing and Machine Learning Methods for Adverse Drug Event Detection in Electronic Health/Medical Records: A Scoping Review.Drug safety · 2025Article
- New Function for Safety Signal Monitoring in MID-NETClinical and translational science · 2025Article
- Pharmacovigilance and bioethics: the importance of a neglected relationship.Frontiers in drug safety and regulation · 2025Review
- Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Infection and infestation-related adverse events of ocrelizumab: A disproportionality analysis using FDA adverse event reporting system.Northern clinics of Istanbul · 2025Article
- Developing electronic health records as a source of real-world data for veterinary pharmacoepidemiology.Frontiers in veterinary science · 2025Article
- Pharmacovigilance - Technological Advancements, Recent Developments and Innovations.Current drug safety · 2025Review
- Optimal Significance Levels and Sample Sizes for Signal Detection Methods Based on Non-constant Hazards.Drug safety · 2024Article
- Predicting Drugs Suspected of Causing Adverse Drug Reactions Using Graph Features and Attention Mechanisms.Pharmaceuticals (Basel, Switzerland) · 2024Article
- An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records.Journal of medical systems · 2024Article
- An open-source implementation of tree-based scan statistics.Pharmacoepidemiology and drug safety · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionPharmacovigilance programs protect patient health and safety by identifying adverse event signals through postmarketing surveillance of claims data and spontaneous reports. Electronic health records (EHRs) provide new opportunities to address limitations of traditional approaches and promote discovery-oriented pharmacovigilance.
methodsTo evaluate the current state of EHR-based medication safety signal identification, we conducted a scoping literature review of studies aimed at identifying safety signals from routinely collected patient-level EHR data. We extracted information on study design, EHR data elements utilized, analytic methods employed, drugs and outcomes evaluated, and key statistical and data analysis choices.
resultsWe identified 81 eligible studies. Disproportionality methods were the predominant analytic approach, followed by data mining and regression. Variability in study design makes direct comparisons difficult. Studies varied widely in terms of data, confounding adjustment, and statistical considerations.
conclusionDespite broad interest in utilizing EHRs for safety signal identification, current efforts fail to leverage the full breadth and depth of available data or to rigorously control for confounding. The development of best practices and application of common data models would promote the expansion of EHR-based pharmacovigilance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.